Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

BACKGROUND: This report provides a survival update at a follow-up of >5 years (5.5–6 years) for patients with advanced melanoma who previously received ipilimumab in phase II clinical trials. Safety and efficacy data following ipilimumab retreatment are also reported. PATIENTS AND METHODS: Patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Oncol
Main Authors: Lebbé, C., Weber, J. S., Maio, M., Neyns, B., Harmankaya, K., Hamid, O., O'Day, S. J., Konto, C., Cykowski, L., McHenry, M. B., Wolchok, J. D.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2014
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4990834/
https://ncbi.nlm.nih.gov/pubmed/25210016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu441
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados